News Quantified

SMMT – summit therapeutics inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Summit Therapeutics (SMMT) is now covered by Citigroup Inc.. They set a "buy" rating on the stock.

Summit Therapeutics (SMMT) is now covered by Stifel Nicolaus. They set a "buy" rating and a $45.00 price target on the stock.

A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing [Yahoo! Finance]

Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's Changed [Yahoo! Finance]

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

0.2%

BEAT

-4.3%

BEAT

-3.2%

MISS

12.3%

BEAT

Stifel Nicolaus

Stifel Nicolaus

Form DEFA14A Summit Therapeutics Inc.

Form ARS Summit Therapeutics Inc. For: Dec 31

Form DEF 14A Summit Therapeutics Inc. For: Apr 17

Form PRE 14A Summit Therapeutics Inc. For: Apr 06

Form S-8 Summit Therapeutics Inc.

Top News Gainers

4/14 Summit Appoints Robert W. Duggan as Chief Executive Officer 27.7%

3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%

6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%

12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%

12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%

7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%

3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%

10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%

2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%

12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%

Top News Decliners

5/1 SUMMIT THERAPEU/S (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock. -12.0%

10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%

12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%

10/11 Half-year report -5.7%

10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%

5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%

11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%

1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%

4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%

7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day